Jacques Dumas

Chief Scientific Officer at Arrakis Therapeutics

Speaker

Jacques Dumas grew up in France and has over 30-years antiinfective and oncology experience. Jacques is currently Chief Scientific Officer (CSO) at AiCuris, a clinical-stage biotech company focused on viral infections in immuno-compromized patients, where he oversees non-clinical activities in support of pritelivir (registration) and AIC-468 (Ph1) development. Between 2020 and 2024 Jacques worked at Arrakis, a company focused on small molecules targeting RNA, first as SVP then CSO. From 2015 to 2019, Jacques was CSO at Tetraphase, a publicly traded company focused on fully-synthetic tetracyclines where he supported the early pipeline and the US/EU eravacycline approvals. Before joining Tetraphase, Jacques was CSO at Idenix (acquired by Merck in 2014) working on liver-targeted nucleosides for the treatment of Hepatitis C. Between 1992 and 2013, Jacques assumed a variety of R&D roles at AstraZeneca and Bayer.